Expanded Access for LJPC-501
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03245528|
Expanded Access Status : Approved for marketing
First Posted : August 10, 2017
Last Update Posted : March 8, 2018
|Condition or disease||Intervention/treatment|
|Catecholamine Resistant Hypotension (CRH) Distributive Shock High Output Shock Sepsis Vasodilatory Shock||Drug: LJPC-501|
The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.
The secondary objective of the study is to assess the safety of LJPC-501.
|Study Type :||Expanded Access|
|Expanded Access Type :||Treatment IND/Protocol|
|Official Title:||Expanded Access for LJPC-501|
- Drug: LJPC-501